Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 15/20 | 0.42 |
| ▸ | CDK2 | P24941 | 15/20 | 0.42 |
| ▸ | CCND1 | P24385 | 12/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916495 | 0.88 | CDK2 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL916708 | 0.86 | TNK2 (0.49) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL916683 | 0.85 | MAPK14 (0.47) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL917525 | 0.84 | CCNE1 (0.59) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL915589 | 0.84 | MAPK14 (0.43) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3576421 | 0.83 | MAPK14 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3674787 | 0.81 | CCNE1 (0.53) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3677090 | 0.80 | CCNE1 (0.55) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3677034 | 0.80 | CCNE1 (0.55) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3577496 | 0.79 | MAPK14 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| EP-2066661-A2 | PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008035316-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | CCNE1 3442/4885CDK2 827/4885CCND1 3084/4885 |
| US-20090221664-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | ADRB2, ADRB1, ADRA2C | CCNE1 4437/4885CDK2 1168/4885CCND1 4363/4885 |
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | CCNE1 3629/4885CDK2 967/4885CCND1 3106/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | CCNE1 2955/4885CDK2 912/4885CCND1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.